Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine for impulsivity in highly impulsive Tourette syndrome patients
2019-004455-36Phase 2Terminated
- Sponsor
- CHU de Poitiers
- Start
- Nov 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of atomoxetine in Tourette syndrome (TS), sponsored by CHU de Poitiers. Primary endpoint: Stop Signal Reaction Time variation. Started Nov 2019; status: terminated.
02
Drugs
atomoxetine
03
Conditions
Tourette syndrome (TS)
Beyond the preview
Go deeper on 2019-004455-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2019-004455-36.